Development of Cagrilintide, a Long Acting Amylin Analogue Journal of Medicinal Chemistry Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth